Exosome-Based Transfection by Homsy, Michael
 
 
 
 
 
Exosome-Based Transfection 
 
Honors Research Thesis 
By Michael Homsy 
Department of Chemical and Biomolecular Engineering 
The Ohio State University 
May 2016 
 
 Presented in partial fulfillment of the requirements for graduation with “Honors 
Research Distinction” in Chemical Engineering 
 
Thesis Committee:  
Dr. L. James Lee, Advisor 
Dr. David Wood 
  
 
 
Abstract 
Exosomes are mammalian extracellular vesicles that are involved in intracellular 
communication. The discovery of RNA in exosomes established their capacity to function as 
RNA delivery vehicles in gene therapy applications. The main obstacle to the gene therapy 
approach is finding suitable vehicles to deliver therapeutic genetic molecules. Conventional 
delivery methods employ viruses or liposomes, however, the clinical applications of these 
vehicles are limited by shortcomings such as cytotoxicity and immunogenicity. On the other 
hand, exosomes could represent a more effective delivery vehicle because they are natural 
transporters of RNA. The purpose of the research presented in this thesis was to investigate the 
transfection ability and cytotoxicity of exosomes. Exosomes were used to transfect mouse 
embryonic fibroblasts (MEFs) in vitro with mRNA for Ascl1, Brn2 and Myt1l (ABM), a 
combination of transcription factors that reprograms fibroblasts into neurons. The exosomes 
were prepared by isolating them from the supernatant of MEFs transfected with ABM plasmids 
using bulk electroporation (BEP). Exosome cytotoxicity was compared to that of a commercial 
liposome formulation by incubating them with MEFs and determining cell viability. The results 
indicate that exosomes successfully transfected MEFs with ABM mRNA. In addition, the 
exosomes were less cytotoxic than the liposomes. In fact, viability of MEFs was minimally 
impacted by incubation with the exosomes. Further research in exosome-based transfection could 
one day allow researchers to harness their intrinsic properties with the purpose of delivering 
RNA for gene therapy.
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Introduction 
Extracellular vesicles have recently gained attention for their role in intercellular 
communication. Because they facilitate the transmission of signals between cells, extracellular 
vesicles have the potential to be used in the delivery of therapeutics [1].  Exosomes are nano-
sized (40-100 nm) mammalian extracellular vesicles. These vesicles lack organelles but are 
composed of cytosol surrounded by a lipid bilayer membrane. Cells begin to form exosomes 
when membrane-bound proteins are endocytosed into the early endosome (EE) [2]. Then, the 
late endosome (LE) invaginates to form internal vesicles and multivesicular bodies (MVB) 
which release exosomes extracellularly upon fusion with the plasma membrane (Figure 1).  
 
 
Figure 1: Illustration of exosome biogenesis and release [2].  
 
 Initially, exosomes were described as vehicles for clearing cell debris and unwanted 
molecules. However, in 1996 an experiment indicated that exosomes participate in antigen 
presentation because exosomes from B cells were shown to induce T cells [3]. In another study, 
exosomes derived from dendritic cells were able to trigger mice immune systems to eliminate 
tumors [4]. Exosomes have since been discovered to be involved in many more immunological 
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functions and in areas such as pregnancy, cancer and neurodegenerative diseases [5]. Besides B 
cells, T cells and dendritic cells, exosomes have been shown to be secreted by numerous other 
mammalian cell types, including tumor cells, epithelial cells and platelets [6]. Studies have also 
reported that exosomes are found in a range of body fluids such as amniotic fluid, blood and 
urine [7].  
An important breakthrough in 2007 was the discovery of mRNA and microRNA in 
exosomes [8]. The study also revealed that the mRNA was functional because it was successfully 
translated into proteins in vitro, and demonstrated that incubation with exosomes from a murine 
cell line resulted in the expression of murine proteins in human cells. This breakthrough revealed 
that exosomes have a natural ability for the transfer of genetic material, and as such, it 
established their potential to function as delivery vehicles in gene therapy applications.  
Gene therapy is the delivery of genetic molecules or nucleic acids for therapeutic 
purposes. This approach is currently the subject of substantial research on afflictions such as 
cancer and neurological diseases [9]. A significant obstacle to the gene therapy approach is 
finding an effective nucleic acid delivery vehicle to protect genetic molecules from degradation 
and facilitate their uptake by cells [10]. Ideally, a nucleic acid delivery vehicle should be capable 
of targeting the specific cell type of interest and delivering the cargo intracellularly without 
inducing an immune response or producing harmful side effects [11]. The most prevalent 
delivery methods in gene therapy are viruses and liposomes (Figure 2).  
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Figure 2: Methods used in gene therapy clinical trials worldwide [12].  
 
Viruses are infectious agents that replicate by infiltrating host cells and using their 
cellular organization for the expression of viral genes. In gene therapy, viral genes that lead to 
viral replication and host cell toxicity are replaced with therapeutic genes. The outcome is a virus 
that uses its highly evolved infection pathway to deliver therapeutic genes to cells. However, the 
use of viral-based delivery vehicles or viral vectors has major disadvantages [13]. One issue is 
the inflammatory response that can ensue if a host immune system is triggered by the presence of 
foreign viral vectors. Another problem is the difficulty in targeting specific cell types, which can 
lead to unwanted gene delivery. In addition, viral vectors derived from retroviruses can lead to 
insertional mutagenesis, the integration of DNA that disrupts a sequence. This could induce 
cancer if the sequence is linked to malignancy. Furthermore, the production of viral vectors is 
typically complex and expensive. 
Liposomes are the most prevalent non-viral nucleic acid delivery vehicles. They are 
vesicles formed by the self-assembly of lipid molecules, which are composed of hydrophilic 
heads and hydrophobic tails. When dissolved, lipid molecules arrange themselves into lipid 
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bilayer membranes to maximize energetically favorable interactions. Eventually, these bilayer 
membranes curve to close the edges and form liposomes (Figure 3) [14]. In gene therapy, 
artificial liposomes are prepared using cationic lipids that can interact with the negatively 
charged backbone of nucleic acids to form complexes with genetic molecules. These complexes 
can be used to efficiently deliver the genetic molecules because liposomes easily fuse with the 
lipid bilayer membrane of cells [15]. Like viruses, the use of liposomes for delivery has its 
limitations [11]. For example, some liposomes have been shown to be toxic. They are also 
limited by a low efficiency of loading.  
 
 
Figure 3: Lipid molecules in solution form bilayer membranes then liposomes [14].  
 
The delivery of therapeutic RNA via exosomes represents a feasible alternative to 
conventional delivery methods since it does not share the shortcomings that limit their clinical 
application in gene therapy. This approach seeks to exploit the intrinsic function of exosomes in 
intercellular communication and harness their natural ability to transport RNA. A crucial feature 
of exosomes that makes them suitable for RNA delivery applications is their size (40-100 nm), 
which is on the order of nanoparticles [16]. Particles circulating within the blood stream are 
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cleared by phagocytotic cells of the reticuloendothelial system if they are too large (250-1000 
nm). On the other hand, particles that are too small (1-30nm) will leak into surrounding tissue 
through extravasation. Exosomes are thus just the right size to avoid these problems and 
maximize circulation. In addition, exosomes are naturally derived and present in many biological 
fluids, suggesting they are safe in vivo.  
A study in 2011 was the first proof-of-concept for exosomes in gene therapy [17]. 
Dendritic cells were collected from mice and engineered to express a brain targeting peptide 
connected to a protein found in exosome membranes. Consequently, exosomes derived from 
these dendritic cells carried the targeting peptide in their membranes. These exosomes were 
loaded with siRNA using electroporation and administered intravenously to mice. The 
researchers demonstrated that the targeting peptide successfully directed exosomes to the brain. 
Furthermore, exosomes loaded with therapeutic siRNA were shown to reduce expression of a 
protein that is involved in Alzheimer’s disease, a neurodegenerative condition. This study is 
important because it offers insight into the feasibility of using exosomes in gene therapy. Not 
only were the exosomes capable of protecting the siRNA cargo, but they specifically delivered it 
to the organ of interest. The exosomes also proved to be immunologically inert because they did 
not induce an immune response.  
The objective of the research presented in this thesis was to investigate the transfection 
ability and cytotoxicity of exosomes. Transfection is the introduction of genetic molecules into 
cells. It can be either stable or transient. In stable transfection, the genetic molecules are 
assimilated into the genome of cells. On the other hand, in transient transfection, the genetic 
molecules are only briefly present in cells. Since exosomes are limited to transporting RNA, they 
can only be used for transient transfection. In this research, exosomes were used to transfect cells 
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with mRNA for the purpose of cell reprogramming, a gene therapy approach in which transient 
transfection is sufficient [18].  
Cellular differentiation is affected by chemical and physical conditions [19]. Lineage-
specific transcription factors determine cell types by influencing gene expression. Differentiation 
was considered to be an irreversible process. However, a major breakthrough in 2006 established 
that fully differentiated cells could be reprogrammed using transcription factors [20]. 
Specifically, these researchers demonstrated that the introduction of four transcription factors 
into mouse fibroblasts successfully induced them into pluripotent stem cells. Another study in 
2010 showed that transcription factors could be used to reprogram differentiated cells directly 
into a different cell type, bypassing the pluripotent cell intermediate [21]. In this case, mouse 
fibroblasts were directly reprogrammed into neurons by expression of a combination of three 
transcription factors, Ascl1, Brn2 and Myt1l (ABM).  
The research presented in this thesis uses exosomes to transfect mouse fibroblasts with 
ABM mRNA. ABM was chosen because it is a well-established model for the reprogramming of 
fibroblasts into neurons. This research also evaluates the cytotoxicity of exosomes compared to 
that of a commercial in vitro liposome formulation.  
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Methods 
Plasmid Preparation 
 Ascl1-GFP, Brn2-RFP and Myt1l-CFP pCAGGS plasmids were obtained from Addgene. 
E. coli were grown at 37 ˚C for 16-18 hours in autoclaved Luria-Bertani (LB) medium and 
ampicillin (.1%). The cells were harvested by centrifugation (4,000 × g, 30 min, 4 ˚C). A 
QIAfilter Plasmid Maxi Kit (Qiagen) was used to extract the plasmid DNA. First, alkaline lysis 
buffers were added and the lysates filtered out. The remaining solution was passed through 
another filter where the DNA was bound, washed and eluted. Isopropanol was added to 
precipitate the DNA. Then, Tris-EDTA (1X TE) buffer was used to resuspend the DNA pellet. 
Finally, a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific) was used to quantify 
DNA concentration. The plasmids were stored at -20 ˚C.   
Bulk Electroporation 
 Bulk electroporation (BEP) is a physical method of transfection. It works by applying an 
electric field to a solution of cells and genetic molecules. The electric field increases the 
permeability of the cells’ membranes, allowing the genetic molecules to diffuse intracellularly 
[22].  
 BEP was used to transfect mouse embryonic fibroblasts (MEFs) with the ABM plasmids. 
This was accomplished using a Neon Transfection System (Invitrogen). A suspension of MEFs 
(1 × 106 cells in 100 µL) was mixed with a combination of plasmids (0.05 µg/µL) at a molar 
ratio of 2:1:1 (Ascl1:Brn2:Myt1l). The resulting mixture was loaded into the Neon pipette tip. 
Then, the pipette was plugged into the Neon transfection device in a tube containing electrolytic 
buffer. Electroporation was conducted using the manufacturer’s recommended setting for MEFs 
(one 30 ms pulse of 1350 V). Finally, the cells were centrifuged and incubated in exosome-
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depleted media. Electroporation settings other than the manufacturer’s recommendation were 
attempted but resulted in a significant decrease in cell viability.  
Exosome Isolation 
 Exosomes were isolated from the supernatant of electroporated MEFs 48 hours after they 
were transfected with ABM. This was accomplished using ExoQuick-TC (System Biosciences), 
a polymer-based exosome precipitation kit. The supernatant was first centrifuged (3,000 × g, 15 
min, 4 ˚C) to remove cells and cell debris. ExoQuick-TC exosome precipitation solution was 
added at a volume ratio of 1:3 (precipitation solution: supernatant). The resulting solution was 
refrigerated overnight at 4 ˚C. Then, exosomes were isolated from the solution by centrifugation 
(1,500 × g, 30 min, 4 ˚C).  
RNA Isolation 
 A mirVana miRNA Isolation Kit (Life Technologies) was used to isolate RNA from 
exosomes. The exosomes were first lysed using the Lysis/Binding Solution (500 µL). Then 
miRNA Homogenate Additive (50 µL) was added. RNA extraction was achieved using Acid-
Phenol: Chloroform (500 µL) and centrifugation (10,000 × g, 5 min) to separate the aqueous and 
organic layers. The extracted aqueous layer was mixed with ethanol (100%, 625 µL). A filter 
was used to bind and wash the RNA. Finally, the RNA was eluted using DEPC-treated water and 
stored at -80 ˚C.  
 To isolate RNA from MEFs, TRIzol Reagent (Life Technologies) (300 µL) was used to 
lyse the cells. RNA was then extracted using chloroform (60 µL) and centrifugation (12,000 × g, 
15 min, 4 ˚C) to separate aqueous and organic layers. Isopropanol was used to precipitate the 
RNA in the aqueous layer, and the solution was centrifuged (12,000 × g, 10 min, 4 ˚C). The 
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pellet was washed with ethanol. After the RNA pellet was left to air dry, it was resuspended in 
DEPC-treated water and stored at -80 ˚C.  
NanoDrop 2000 was used to determine RNA concentration.  
Polymerase Chain Reaction 
  Reverse transcription polymerase chain reaction (RT-PCR) was used to produce cDNA 
from the RNA isolated previously. Each sample was prepared using a High Capacity cDNA kit 
(Invitrogen) by mixing reverse transcriptase buffer (10X, 2 µL), dNTPs (100 mM, 0.8 µL), 
Random Primers (2 µL), reverse transcriptase (1 µL), RNase inhibitor (1 µL) and the RNA in 
nuclease-free water (100 ng, 13 µL). A Veriti Thermal Cycler (Applied Biosystems) was loaded 
with the samples and run according to the manufacturer’s protocol.  
cDNA generated from RT-PCR was then used in real-time PCR (qPCR) to quantify the 
ABM mRNA originally present. Each sample was prepared by mixing iQ SYBR Green 
Supermix (Bio-Rad) (5 µL), forward primer (0.2 µL), reverse primer (0.2 µL), nuclease-free 
water (3.6 µL) and the cDNA (1 µL). The samples were then loaded into a StepOnePlus Real-
Time PCR System (Applied Biosystems), which was subsequently run according to the 
manufacturer’s protocol.    
Liposome Preparation 
 Liposomes were prepared using the commercial Lipofectamine 2000 Reagent (Life 
Technologies), a cationic liposome formulation used for in vitro applications. The liposomes 
were produced according to the manufacturer’s protocol by mixing the Lipofectamine reagent 
with a combination of plasmids (0.05 µg/µL) at a molar ratio of 2:1:1 (Ascl1:Brn2:Myt1l). For 
the cytotoxicity experiment, this mixture was incubated with MEFs (3 × 105 cells per well) for 
48 hours.   
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Results 
 Fluorescence microscopy was used to image MEFs 48 hours after transfection with ABM 
plasmids using BEP (Figure 4). The green fluorescence resulted from expression of the green 
fluorescent protein (GFP) tagged to Ascl1 plasmids. This indicates that the BEP transfection of 
MEFs with Ascl1 plasmids was successful.  
 
  
Figure 4: Green fluorescence due to expression of GFP tag on Ascl1 plasmids.  
 
 RNA was isolated from the MEFs 48 hours after transfection with ABM plasmids. The 
amount of ABM mRNA was quantified using qPCR after RT-PCR (Figure 5). There was an 
increase in Ascl1 mRNA compared to untreated control MEFs. However, Brn2 and Myt1l mRNA 
content was found to be lower than control.  
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Figure 5: qPCR of ABM mRNA from MEFs 48 hours after transfection with ABM plasmids 
using BEP. 
 
 Exosomes were derived from the MEFs 48 hours after they were transfected. RNA was 
isolated from these exosomes and qPCR was used to quantify their ABM mRNA content (Figure 
6). The Ascl1, Brn2 and Myt1l mRNA content of the exosomes showed an increase from that of 
control exosomes derived from untreated MEFs.  
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Figure 6: qPCR of ABM mRNA from exosomes. 
 
 These exosomes were incubated with a fresh set of MEFs for 48 hours. To determine 
whether the exosomes transfected the cells, RNA was isolated from the MEFs and qPCR was 
used to quantify the cells’ ABM mRNA content (Figure 7). It was found that exosomes 
transfected the MEFs because the cells showed an increase in ABM mRNA compared to 
untreated cells.   
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Figure 7: qPCR of ABM mRNA from MEFs 48 hours after incubation with exosomes derived 
from transfected MEFs. 
 
 To investigate exosome cytotoxicity, MEFs were incubated with exosomes derived from 
transfected MEFs and ABM plasmid-loaded liposomes prepared using Lipofectamine reagent. 
After 48 hours, MEFs incubated with exosomes demonstrated a 94% viability of control, while 
those incubated with liposomes had a 28% viability (Figures 8 & 9).    
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Figure 8: (A) Untreated MEFs. MEFs incubated with (B) exosomes and (C) liposomes for 48 
hours. 
 
 
Figure 9: MEF viability after incubation with exosomes and liposomes for 48 hours. 
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Discussion 
 The low quantities of Brn2 and Myt1l mRNA in electroporated MEFs (Figure 5) and their 
exosomes (Figure 6) could be attributed to an unsuccessful transfection of the MEFs with Brn2 
and Myt1l plasmids. Since it is diffusion dependent, BEP is known to cause stochastic 
transfections [23, 24, 25, 26]. Additionally, the Brn2 (1.3k bp) and Myt1l (3.5k bp) gene inserts 
are much larger than the Ascl1 (0.7 k bp) gene insert, and as such, their plasmids would have 
diffused more slowly into cells during BEP. Future work will investigate whether electroporated 
MEFs were actually transfected with the Brn2 and Myt1l plasmids. Another possible explanation 
for the low quantities of Brn2 and Myt1l mRNA in electroporated MEFs and their exosomes 
could be gene silencing of Brn2 and Myt1l. This would also account for the observed decrease in 
Brn2 and Myt1l mRNA in cells after electroporation (Figure 5). Future work will therefore 
examine whether gene silencing was affecting the Brn2 and Ascl1 mRNA content.    
 Exosomes derived from electroporated MEFs successfully transfected cells in vitro with 
ABM mRNA (Figure 7). However, the cells’ mRNA increased to a similar extent for all three 
transcription factors, despite the fact that the exosomes used were loaded with considerably 
lower proportions of Brn2 and Myt1l mRNA than Ascl1 mRNA (Figure 6). Future work will 
focus on determining a cause for these strange results. In addition, future work will investigate 
whether MEFs transfected with exosomes express the ABM transcription factors and undergo 
reprogramming into neurons.   
 The cytotoxicity experiment showed that cell viability is minimally impacted upon 
incubation with exosomes. It also demonstrated that exosomes are less cytotoxic than a more 
conventional method for the delivery of nucleic acids. However, it must be noted that the 
liposomes used were prepared using a commercial Lipofectamine reagent intended for in vitro 
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transfection. As such, this formulation was designed to maximize transfection efficiency rather 
than limit cytotoxicity. Future work will compare the cytotoxicity of exosomes with liposome 
formulations meant for in vivo applications which are less cytotoxic than Lipofectamine.  
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Conclusion 
 Exosomes are natural intercellular transporters of RNA that are involved in various 
functions in vivo. Due to their intrinsic properties, exosomes could represent a more effective 
method for RNA transfection in gene therapy than conventional nucleic acid delivery vehicles. 
The research presented in this thesis used exosomes for the in vitro transfection of fibroblasts 
with mRNA for ABM, a combination of transcription factors that reprograms fibroblasts into 
neurons. Furthermore, the cytotoxicity of exosomes was investigated and found to be less than 
that of a common in vitro transfection method.  
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